Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy.

Abstract

We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was adifference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of anew primary tumor (NP). The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40patients with IBTR. Propensity score matching was employed to select 40trios (120 patients) consisting of 1patient with IBTR and 2patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens. The 40patients with IBTR included 22patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP. IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.